ACTR8

Across TCGA pan-cancer cohorts, ACTR8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACTR8 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACTR8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACTR8 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ACTR8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.510	0.228	.003	29	view →
LSCC	OS	Tertile	II,III,IV	0.957	0.636	.002	29	view →
LUAD	OS	Tertile	All	0.989	0.606	.006	17	view →
OV	DFS	Median	All	1.000	0.848	.024	8	view →
HNSC	OS	Median	II,III,IV	0.617	0.803	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACTR8–PDAC (DFS)

Open the PDAC breakdown →